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i 
Abstract 
 
Sixteen bryozoan species from the United Kingdom and New Zealand were 
surveyed for the presence of brominated secondary metabolites by Liquid 
Chromatography tandem Mass Spectrometry (LCMS) analysis. Brominated 
metabolites were detected in six of these samples. Collections of the species 
Amathia citrina and Amathia verticillata were determined as ideal candidates for 
a natural products study due to the presence of potentially novel brominated 
secondary metabolites in reasonable abundance.  
 
The sample with the greatest number and seemingly highest concentration of 
brominated secondary metabolites, of all species surveyed, was the species 
Amathia citrina (previously Bowerbankia citrina) from Swansea, Wales, and so 
was selected as the candidate for this study.  
 
Eight related metabolites were detected in A. citrina, speculated to be a family of 
brominated alkaloids. Attempts were made to isolate and purify two members of 
this family of compounds by reversed-phase and size exclusion chromatography, 
but were unable to be obtained in a pure state. Nevertheless, they were then 
partially characterised by mass spectrometry (MS) and nuclear magnetic 
resonance (NMR) spectroscopy to be discovered as a new family of brominated 
indole alkaloids, tentatively named the amathamines. 
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1 Chapter One 
Introduction 
 
1.1 Natural Products 
 
Natural products have been the best source of mankind’s lifesaving medicines. 
The treatment of infectious diseases, cancer and immunological disorders have all 
had breakthroughs due to natural products. The metabolites of a living cell are 
classified two-fold: primary metabolites, which are used by cells for their own 
sustenance and growth such as carbohydrates, lipids and amino acids, and 
secondary metabolites, which are biosynthesised from primary metabolites for 
other purposes. It is these secondary metabolites that have pharmaceutical 
potential and make up the lead chemicals extracted in a natural products study.  
Plants, bacteria, fungi and marine invertebrates are the major foci of these 
studies.1  
 
Historically, terrestrial plants have been the source of most medicines for the 
treatment of diseases, and were administered as crude or semi-pure extracts. Not 
until the purification and characterisation of individual components from these 
extracts, in the early nineteenth century, were the effects of these mixtures 
attributed to the pure compounds responsible. Then began a new era of medicine 
where drugs were purified and administered in precise dosages. In 1817, Friedrich 
Seturner reported colourless crystals, possessing the narcotic properties of opium, 
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from precipitation of a hot water extraction of the plant Papaver somniferum 
(Opium Poppy), the first ever alkaloid to be reported from a plant.2 A pharmacist 
named Emanuel Merck industrialized and marketed this extraction of opium in 
1827, developing the first commercial and pure natural product, morphine.3 
Examination of terrestrial fungi extracts in the early twentieth century led to the 
discovery that microorganisms are also important sources of pharmacologically 
relevant natural products. In 1929, Alexander Fleming discovered the penicillins, 
from the fungus Penicillium chrysogenum,4 the most active being penicillin G, 
which later became the most famous life-saving natural product-based drug of 
recent history.5 
 
From the middle of the twentieth century onwards, the field of marine chemical 
ecology matured into a well-developed science. Benthic communities in tropical 
and temperate waters were found to be rich in valued secondary metabolites.6 
From these benthic communities, a significant number of cytotoxic and antibiotic 
compounds have been discovered. Cytarabine (1), a C-nucleoside isolated from 
the sponge Cryptotheca crypta in the 1950s, was the first marine-derived drug 
used clinically.7 However, this success did not correspond to an influx of new 
drug candidates, due to the decreased interest by the pharmaceutical industry in 
natural products research during the middle and late twentieth century. Instead, 
such companies focused on combinatorial chemistry for drug discovery.8 Yet, the 
higher success rate of marine natural products in drug discovery (1 in every 3140), 
over that of combinatorial chemistry (1 in every 5000-10,000), has led to a 
renewed interest in marine natural products research for the purposes of drug 
discovery.9 Narrowing down the focus to natural products from marine 
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invertebrates has been proven to be an effective strategy for discovering drug-like 
leads. Since invertebrates use secondary metabolites as chemical defences to ward 
off predators (possible cytotoxic effects) and microfouling organisms (possible 
anti-infective effects)  these compounds have already been attested by nature and 
so have been optimised to be bioactive through evolutionary selection.10 
 
(1) 
 
The majority of marine natural products research has been focused on invertebrate 
phyla other than Bryozoa. In recent years (2011-2013), the annual “Marine 
Natural Products reviews” in the journal Natural Product Reports have noted a 
sum total of 2887 citations referring to compounds isolated from marine 
microorganisms and phytoplankton, green, brown and red algae, bryozoans, 
tunicates, cnidarians, sponges, molluscs, echinoderms, mangroves and other 
intertidal plants and microorganisms, reporting 3169 new compounds. Of the 
2887 citations, only 25 concern bryozoan research, with only 16 novel compounds 
and one revised structure reported. In comparison to the phylum Porifera 
(Sponges) for which there were a sum total of 526 citations, reporting 655 novel 
structures, Bryozoa remains a minimally explored phylum.11-13  
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The volume of bryozoan natural products research is unjustifiably small. Many 
novel compounds isolated from bryozoans (or a dependant symbiont) hold potent 
biological activities. Bryostatin 1 (2), isolated from the bryozoan Bugula neritina, 
has been shown to reduce malignant melanoma, lymphoma, and ovarian 
carcinoma tumours in Phase I trials.14,15 Bryostatin 1 has also been through Phase 
II trials for treatment against non-Hodgkin’s lymphoma and chronic lymphocytic 
leukaemia.16 Additionally, treatment with bryostatin 1 and analogues shows 
promise to efficiently overcome the largest obstacle to the eradication of the 
Human Immunodeficiency Virus (HIV), presence of latent proviral reservoirs. 
Bryosatin 1 and analogues have been shown to modulate the signalling pathways 
associated with HIV viral reactivation in order to help lower the proviral pool of 
HIV in Acquired Immune Deficiency Syndrome (AIDS) patients, thus allowing 
antiviral medicines and natural immunological processes to work on the active 
virus. Currently, the time taken to potentially cure AIDS patients is expected to 
take many decades in patients only treated with the leading antiviral drugs.17,18 
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(2) 
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1.2 Biohalogenation  
An organism’s ability to modify chemical functionality of secondary metabolites 
directly modifies their bioactivity. One such example is nature’s ability to 
halogenate these secondary metabolites with specific and non-specific 
halogenases. A plentiful number of halogenated natural products have been 
isolated in recent years. As of 2010, the number exceeded 4700 with 
approximately 2100 discovered from marine organisms.19 The concentration of 
chloride in the oceans is approximately 19,000 mg/L, which far exceeds the 
concentration of bromide at about 65 mg/L. Despite this, bromination is, in the 
majority, a distinct functionality of marine natural products whilst chlorination is 
instead favoured by terrestrial organisms. Marine organisms are more readily able 
to oxidise bromine, and so it can be more easily incorporated into a molecule.20,21  
 
Nature utilises enzymes to halogenate molecules. Bromoperoxidase is an enzyme 
commonly used to brominate molecules. There are two classes of halogenating 
enzymes; the highly specific halogenases, which require oxygen, or the less 
specific haloperoxidases that require peroxide, of which bromoperoxidase is an 
example. Haloperoxidases are divided into two classes; haem iron-dependent 
peroxidases and vanadium-dependent peroxidases. These enzymes generate the 
electrophilic halogenating species hypohalous acid. The mechanism of these 
haloperoxidases requires electrophilic activation by reaction of the halide with 
peroxide, under the assistance of the enzyme. The nucleophile to be halogenated 
reacts with the released hypohalous acid, which can result in multiple 
halogenations.22 On account of this, it can be argued that these less specific 
peroxidases are not primarily halogenating enzymes, as halogenated natural 
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products hold specific regiospecificity. Instead, they can be used so when taken 
out of their native context.19 However, controlled haloperoxidase reactions have 
been reported by the bioprocess department of Merck in the synthesis of 
Indinavir, and by Kaysser and co-workers for the synthesis of merochlorins A–D, 
among others.23,24  
 
The more specific halogenases that use oxygen are classified into two categories; 
those that utilise flavin (the flavin-dependent halogenases) and those that utilise 
iron (the non-haem iron-dependent halogenases). Halogens are oxidised in the 
flavin-dependent halogenases by oxygen via reaction with flavin. The hypohalous 
acid is released and travels to the substrate which is bound to the enzyme at 
another site. This enzymatic process can halogenate electron-rich, or activated 
sites on indoles and pyrroles.25,26 Non-haem iron-dependent halogenases do not 
require electron-rich substrates, instead the oxo-ferryl intermediate formed is 
sufficiently reactive to transfer halogens by removal of a hydrogen to form a 
reactive radical substrate.27 
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1.3 Phylum Bryozoa 
 Bryozoans are sessile, colonial invertebrates of benthic marine, and sometimes 
freshwater, environments. They are filter feeding animals and have been 
commonly referred to as moss mats or moss animals. Bryozoans were historically 
miss-identified as plants due to some species having seemingly plant like 
appearances.28 The phylum Bryozoa has three classes, Phylactolaemata, 
Stenolaemata and Gymnolaemata.29 A taxanomic classification is outlined in 
figure 1.1 below.  
 
Figure 1.1. Bryozoa taxa. Orders of Bryozoa. (Adapted from reference 29).  
  
Bryozoans live in colonies called zoaria. An individual is termed a zooid, and 
some contain specialised morphology. An autozooid, depected in figure 1.2, is the 
basic organizational unit of a colony, which bears the lophophore and digestive 
parts, some zooids specialise into brood chambers or interconnecting packing 
cells, generally termed heterozooids. A colony arises from a single ancestral 
individual, which buds repeatedly to form a colony of connected zooids.29 
Bryozoans contain excreted exoskeletons called zoecia. The composition of a 
zoecium can differ among species. It can be gelatinous, such as in the freshwater 
species, Pectinatella magnifica, found in the Mississippi river, United States of 
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America. This outer covering can also be chitinous, such as that found in species 
of Phylactolaemata and Ctenostomata, or can be calcareous, as in species of 
Stenolaemata and Cheilostomata.30  
 
Bryozoans contain a lophophore for feeding which is a ciliated crown of tentacles 
for the purpose of catching debris from the surrounding water. Additional 
characteristic morphology of a bryozoan is a unidirectional U-shaped gut 
comprised of an esophagus, stomach, cecum, intestine and an ectoproct, an anus 
outside of the lophophore. A Lophophore can be withdrawn for protection. 
Species of the Stelnolaemates family utilise a membranous sac that decompresses 
by expelling fluid into another cavity in order to pull down the lophophoral 
 
Figure 1.2. Typical autozooid morphology. “A zooid of Plumatella (cutaway 
view).” (Adapted from reference 29). 
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tentacles which are attached by ligands. Species of the class Ctenostomata are 
examples of bryozoans that use simple retractor muscles for lophophore 
extraction. The ability of bryozoans to retract their lophophores is characteristic 
among lophophorates.30 
 
Of the three taxonomic classes of Bryozoa, Stenolamata and Gymnolaemata are 
the only orders to contain marine bryozoans. Phylactolaemata is comprised only 
of freshwater Bryozoa. No natural products have yet been reported from any 
freshwater species. Gymnolaemata is predominantly comprised of marine 
Bryozoa with the majority of natural products being isolated from this class.28   
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1.4 Natural Products Isolated from Bryozoans 
1.4.1  Introduction 
Families of alkaloids with at least a single compound containing bromine 
functionality are reported herein. All of the bryozoans reported to contain these 
compounds are from the orders Cheilostomata and Ctenostomatida. This is, 
perhaps, due to these orders belonging to the same class, Gymnolaemata, which 
has the greatest number of species.29 The majority of natural products isolated 
from species of Amathia (additionally Zoobotryon, now Amathia)31 are 
brominated alkaloids. The Genus Amathia is seemingly one of the most 
extensively investigated genera of bryozoans in natural products research. Many 
species of Amathia reported below produce a range of brominated amino acid-like 
compounds based on tryptophan, proline, leucine and tyrosine and it is likely that 
many more additional natural products isolated from species of Amathia will 
follow this trend.       
1.4.2 Survey of Brominated Alkaloids Isolated from Bryozoans  
Studies on Flustra foliacea were among the first on a marine source which 
yielded structurally and pharmacologically interesting alkaloids. The cis-fused 
dipyrrolidine brominated alkaloids, flustramines A (3) and B (4), were extracted 
from F. foliacea. The structures are reminiscent of physostigmine alkaloids of the 
Calabar bean, however they contain the additional feature of bromination. Based 
on the Ultraviolet (UV) absorption spectrum, the extract was purified by standard 
chromatographic methods. Characterisation was also achieved by standard 
methods, namely mass spectrometry (MS) and nuclear magnetic resonance 
(NMR) spectroscopy.32,33 
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(3) (4) 
 
 
Flustramine C (5) and the flustraminols A (6) and B (7) were also isolated from F. 
foliacea. Like the flustramines, flustraminols A and B possess a physostigmine 
skeleton with bromination exclusively at C-6. Another consistent moiety within 
flustramines and flustraminols is the presence of at least one isoprene unit, 
whether it be a 3-methyl-2-butenyl, or the unusual 2-methyl-3-buten-2-yl 
substituent, which is an inverted form of the former. Isolation of compounds (3), 
(4), and (5) was carried out from an ethanol extract using common methods of 
fractionation and chromatography and characterisation was achieved by standard 
methods.34 Methylation at N1 remains consistent within the flustramines and 
flustraminols, whether the isolation procedure used methanol or not, so it is 
improbable that the N1 methyl amide is an isolation artefact. 
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(5) 
 
 
(6) (7) 
 
 
Flustrabromine (8), flustramide A (9) and the brominated tryptamine, 6-bromo-
Nb-methyl-Nbformyltryptamine (10) were also isolated from F. foliacea,35,36 as 
well as the first reported naturally occuring bromo-substituted quinoline, 7-
bromo-4-(2-ethoxyethyl)-quinoline (11). Common extraction and isolation 
methods were used for the flustramines.37  Dihydroflustramine C (12) was isolated 
from a dichloromethane extract of F. foliacea and this protonated form of 
flustramine C showed potent antibacterial activity against Bacillus subtilis.38  
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(8) 
 
 
(9) (10) 
 
 
(11) (12) 
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Flustramide B (13) and flustrarine B (14) were isolated from a Scandinavian 
collection of F. foliacea. A petroleum ether and an ethyl acetate (EtOAc) extract 
were fractionated by High performance Liquid Chromatography (HPLC). 
Characterisation of flustramide B was achieved by comparison of Infrared (IR), 
UV, and NMR spectroscopic data to thoes of flustramide A (9). Flustrarine B had 
similar spectroscopic properties to that of flustramine B (13), however the mass 
spectrum showed the addition of an oxygen to the structure. Structural elucidation 
was achieved by the usual methods.39 
 
 
From a methanol extraction of a Nova Scotian collection of F. foliacea, 
dihydroflustramine C (12) has also been found. However, flustramine C (5), the 
likely precursor to this potent antibacterial compound could not be detected in this 
  
(13) (14) 
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extract. Flustramine D (15), flustramine D N-oxide (16), isoflustramine D (17) 
and dihydroflustramine C N-oxide (18) were also isolated from this sample. The 
crude extracts were chromatographed on a pad of silica gel, then subjected to 
rotating-disc adsorption chromatography and HPLC, piror to characterisation by 
usual methods. 40  Flustramine E (19) and debromoflustramine B (20) have been 
reported from a North Sea sample of F. foliacea,.41 
 
 
 
(17) 
  
(15) (16) 
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(18) 
(19) R=Br 
(20) R=H  
 
 
Fifteen years after the discovery of flustramine E, eleven new flustramines, F-P 
(21-31), were isolated in a 2009 study from dichloromethane extracts of both the 
New Brunswick and Nova Scotian strains of F. foliacea.8 The apparent increase in 
the number of secondary metabolites isolated in one study is contributed, in part, 
to the increased sensitivity of chromatographic and spectroscopic instruments 
available. Unlike in previous studies of the flustamines, two-dimensional NMR 
spectroscopy was utilised for the determination of heteronuclear correlations.42 
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(21) R1 = Ac; R2 = Y; R3, R4, R6 = H; R5 = Br 
(22) R1, R3, R6 = H; R2 = Y; R4, R5 = Br 
(23) R1, R4, R5 = H; R2 = X; R3 = OH; R6 =Br 
(24) R1, R4, R5 = H; R2 = X; R3 = OH; R6 = Br 
(25) R1, R5 = H; R2 = Z; R3 = OH; R4, R6 = Br 
(26) R1, R5 = H; R2 = A; R3 = OH; R4, R6 = Br 
(27) R1, R5 = H; R2, R4 = A; R3 = OH; R6 = Br 
 
 
  
X= 
 
  Y= 
 
  Z= 
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(28) (29) 
  
 
(30) 
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(31) 
 
                                                                                           
The majority of brominated alkaloids isolated from bryozoan species belong to 
the order Cheilostomata such as the Bugulidae, Flustridae and Catenicellidae 
families. The bromopyrrole alkaloids, aspidostomides A-H (32-39), aspidazide A 
(40) and 9-O-ethyl aspidostomide C (41), which were isolated from the 
Patagonian bryozoan Aspidostoma giganteum, were the first obtained from the 
Aspidostomatidae family, and further extended the brominated alkaloids known 
from bryozoans of the order Cheilostomata. Aspidostomides A-H (32-39) were 
extracted then fractionated using silica gel chromatography then purified by 
preparative HPLC. Techniques used during the characterisation of these alkaloids 
reflect the usual analytical tools applied in modern structural elucidation studies. 
Two-dimensional NMR spectroscopy, 1H-1H Correlation Spectroscopy (COSY), 
1H-13C Heteronuclear Single Quantum Coherence (HSQC), 1H-13C Heteronuclear 
Multiple Bond Correlation (HMBC) and Nuclear Overhauser Effect Spectroscopy 
(NOESY) experiments were utilised, as well as High Resolution Mass 
Spectrometry (HRMS) and chemical transformations. Apidostomide E (36) 
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showed activity against the 786-O renal carcinoma cell line. Aspidazide A (40) 
contains a rare N-N linkage between two lactams, yet this could not be 
unambiguously characterised by correlation NMR spectroscopy. Mass spectral 
analysis and NOE correlations between protons of the different parts of the 
molecule gave evidence for the existence of a diacylazide dimeric structure in 
Aspidazide A (40), made up by the union of two C13H5Br4N2O2 moieties. The 
compound was reduced with sodium hydride and methyl iodide in 
dichloromethane in an attempt to confirm the presence of the diacylazide bond. 
Two products, the corresponding monomers with N-methylation and O-
methylation of the phenol functionalities were isolated and characterised 
unambiguously by standard methods.43 
 
 
 
(32) R1=R2=H; R3=Br 
(33) R1=R3=H; R2=Br 
(34) R1=H; R2=R3=Br 
(41) R1=Et; R2=R3=Br 
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(35) R=OH 
(36) R=OMe  
(37) R=H 
 
(38) 
 
(39) 
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(40) 
 
From a San Diego collection of Amathia verticillata (previously Zoobotryon 
verticillatum), the indole derived metabolites 2,5,6-tribromo-N-methylgramine 
(42) and its corresponding N-oxide (43) have been reported. Pure samples of 
compounds (41) and (43) were obtained by standard chromatographic methods.  
Characterisation was achieved by HRMS and NMR spectroscopy. The structures 
were confirmed by comparing the melting point and spectroscopic data of the 
natural products to thoes of the synthesised compounds.44  Interestingly 
compound (42) had already been synthesised before being isolated from a natural 
source.45  
 
A debrominated form of (42), 2,6-dibromo-N-methylgramine (44) has been 
reported from collections of A. verticillata from Cabo Frio and Porto Belo, Brazil, 
as well as from Little Jim and Coon Island, Florida, from a single study. Standard 
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chromatographic and structural analysis methodologies were utilised. Feeding 
experiments were undertaken to establish if the widespread invasion of A. 
verticillata into tropical to warm-temperate waters was due to chemical defences 
against predation. No correlation between concentrations of (42) in samples of A. 
verticillata and feeding deterrence by fishes belonging to Chaetodontidae, 
Haemulidae, Labridae and Pomacentridae families was observed. Every sample of 
A. verticillata containing (42) tested did not deter feeding. This study suggests the 
success of invasion by A. verticillata is not due to chemical defences deterring 
predation.46  
 
 
 
(42)R1=Br, R2=(CH3)2 
(43) R1=Br, R2=O(CH3)2 
(44) R1=H, R2=(CH3)2 
 
 
2,5,6-Tribromo-N-methylindole-3-carbaldehyde (45) was also isolated from A. 
verticillata, however from collections off the Spanish coast, and underwent 
standard chromatographic methods to yield a pure sample of compound (45), as 
well as compounds (41) and (43). Characterisation was carried out by standard 
analytical methodologies. The origin of compound (45) has been hypothesized to 
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be from acetylation of compound (43). This was experimentally shown to occur in 
vitro by reaction of (43) with acetic anhydride in pyridine, which yielded 
compound (45) and was proposed to occur after two successive rearrangements, 
firstly the Polonovski rearrangement, then a rearrangement of the acetoxy moiety 
to acetaldehyde, to give (45). Cell division in sea urchin eggs was potently 
inhibited by compounds (41) and (43). While compound (45) only delayed 
metamorphosis within cell division.47  Pharmacological applications of crude 
extracts from A. verticillata sourced off the coast of India showed anti-
inflammatory and central nervous system stimulation comparable to the positive 
controls of pentazocine and caffeine respectively.48  
 
 
(45) 
 
The bromotryptamine derived alternatamides A-D (46-49) were extracted from a 
sample of Amathia alternata.  The extract was purified by standard methods. 
Structures were elucidated by one- and two-dimensional NMR spectroscopy and 
HRMS.49 Like the flustramines, bromination occurs predominantly at the same 
sites upon the aromatic ring for alternatamides A-D (46-49) as for the 
flustramines. The flustramine compounds (4, 5, 7-11, 13-15) all exhibit 
bromination at C-6, as do the alternatamides A (46),  B (47), and D (49) This is a 
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site commonly brominated in tryptamine/tryptophan-like natural products, 
possibly signifying a relatable metabolic function within marine invertebrates.15 
 
 
(46) R1=Me; R2=R3=Br 
(47) R1=H; R2=R3=Br 
(48) R1=R3=H; R2=Br 
(49) R1=R2=H; R3=Br 
 
 
From the Australasian species A. wilsoni Kirkpatrick, collected off the coast of 
Tasmania, the amathamides A-H, (50-57), tri-, di- and monobrominated proline-
derived compounds have been discovered. All of the amathamides were isolated 
from A. wilsoni except for amathamide G which was isolated from a Tasmanian 
collection of A. convoluta. A methanol extract of A. wilsoni was purified by 
standard chromatographic methods to afford the amathamides A-G. Amathamide 
H was isolated using the unusual method of packing sample adsorbed silica beads 
into a HPLC column then subjecting the sample to multiple HPLC isolation steps. 
Amathamide H was not very soluble in dichloromethane and so remained 
undiscovered in previous studies. The amathamides were characterised by 
standard spectroscopic methods. 50-53 
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(50) R1=R2=H 
(52) R1=Br; R2=Me 
(54) R1=Br; R2; =H  
(56) R1=OCH3; R2; =CH3 
 
(51) R=H 
(55) R=Br 
 
 
 
 
  
(53) (57) 
                                                                                                          
In addition to amathamide H, the wilsoniamines A (58) and B (59), possessing a 
hexahydropyrrolo[1,2-c]imidazol-1-one scaffold previously unreported in nature, 
were isolated from A. wilsoni. Extraction and isolation methods were identical to 
those mentioned for amathamide H. Amathamide C was rediscovered by Carrol 
and co-workers, and found to contain a 2,4,6-tribromo-3-methoxyphenyl moiety 
instead of the 2,3,4-tribromo- 5-methoxyphenyl moiety previously reported.51,52 
Researchers advised that the structures proposed for amathamides C–F (52-55) 
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should be revised so they contain instead the 2,4,6-tribromo-3-methoxyphenyl 
moiety. Wilsoniamines A and B were found to have no antimalarial and 
antitrypanosomal activity, unlike amathamides C (52) and H (57), which showed 
modest activity. It was proposed that a lack of cell permeability influenced the 
wilsoniamines lack of activity. 53 
 
 
(58) (59) 
 
Another family of brominated alkaloids, the amathaspiramides A-F, (60-65) 
respectively, were isolated from a collection of A. wilsoni from Wellington, 
New Zealand. Data from single-crystal X-ray diffraction of amathaspiramide A 
was used for structural conformations and absolute configuration 
determinations. Amathaspiramide E (64) showed strong antiviral activity 
against the type 1 Polio virus. It was demonstrated that no amathamides 
were present in the New Zealand strain. This could be due to genetic 
variation or different environmental conditions. Levels of amathaspiramides 
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were found to be consistent within different populations of A. wilsoni 
collected at the same site.54  
 
It is possible that the differences in brominated alkaloid content between 
Tasmanian and Wellington A. wilsoni populations could be due to differing 
symbiotic bacteria. It has become well known that secondary metabolites from 
marine invertebrates are, at least in part, due to symbiotic bacteria.55 As the 
Tasmanian and Wellington A. wilsoni populations differ and marine bacteria have 
been shown to produce brominated alkaloids, this lends weight to the hypothesis 
that the origin of the amathamides and amathaspiramides is, at least in part, due to 
bacteria. A bacterium, Pseudomonas bromoutillis, has been found to contain a 
2,3,4-tribromo5(1’ hydroxy,2’,4’ dibromophenyl)pyrrole, a compound similar in 
structure to the amathamides.56  
 
  
(60) R1=Me; R2=H 
(62) R1=R2=H 
 
(61) R=Me 
(63) R=H 
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(64) (65) 
  
The leucine and tyrosine derived volutamides A-E (66-70), were isolated from the 
Atlantic species A. convoluta, collected from Morehead City Port, North Carolina. 
The samples were isolated by standard methods, guided by bioactivity of a 
hydroid larvae (Eudendrium carneum) settling bioassay. The structures were 
determined by standard spectroscopic methods as well as by chemical methods. 
Volutamide B (67), and C (68) effectively deterred feeding by predators and 
volutamide B (67) and D (69) were toxic towards larvae of the aforementioned 
hydroid. Therefore these metabolites likely form the basis of the bryozoan’s 
chemical defence.57 
 
(66) 
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(67) R=H 
(68) R=CH3 
 
(69) 
 
(70) 
 
The convolutamines A-J (71-80) are beta-phenylethylamine containing 
metabolites found in A. convoluta and A. tortusa. Convolutamines A-D (71-74), 
were isolated from a collection of A. convoluta from off the coast of Florida. 
Convolutamines A-C (71-73) are monobrominated whilst convolutamine D (74) is 
dibrominated.58 Convolutamines E-G (75-77) were obtained from another 
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collection of A. convoluta off the coast of Florida, and are also dibrominated.59 
Convolutamine H (78) was extracted from an Australian strain of A. convoluta 
collected off the coast of Tasmania along with a tribrominated indole-based 
compound, convolutindole A (81). Convolutamine H  (78) and convolutindole A 
(81) were found to be potent nematocidal agents.60 Convolutamines I (79) and J 
(80) were extracted from another Amathia species, A. tortusa, which was also 
sourced from Tasmania, and both showed toxicity towards the parasite that causes 
Human African trypanosomiasis, Trypanosoma brucei brucei.61 
 
 
 
 
(71) R1=Me; R2=Br 
(72) R1=Me; R2=H 
(73) R1=H; R2=Br 
(74) 
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(75)  (76) 
  
(77)  (78) 
 
 
(79) (80) 
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The dibrominated convolutamides A-F, (82-87), which contain an N-acyl-γ-
lactam moiety, have also been isolated from the bryozoan A. convoluta. A 
collection of A. convoluta from the Gulf of Mexico afforded the convolutamides 
as mixtures of pure compounds.62  Also extracted from a collection of A. 
convoluta sourced from the Gulf of Mexico, were the convolutamydines A-E. The 
convolutamydines (88-92), are based on indole alkaloids with bromination at C-6, 
thus resemble convolutindole A (81).59,63,64 
 
(81) 
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(82) 
            
(83) 
            
(84) 
            
(85) 
           
(86) 
           
(87) 
          
 
  
(88) (89) 
R=     
R=     
R=     
R=     
R=     
R=     
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(90) (91) 
 
(92) 
 
With renewed interest in bryozoans, researchers at Griffith University, Australia, 
have embarked on a programme to investigate the chemistry of temperate and 
subtropic bryozoans of Australia. Previously described compounds discovered 
from this campaign were the wilsonamines A and B and amathamide H. 
Researchers at Griffith University have also discovered new tribrominated indole-
based compounds, kororamide A (93) and B (94). Kororamide A was isolated 
from A. tortuosa using the same methods mentioned as for the isolation of 
Amathamide H. The structure of kororamide A was elucidated by standard 
spectroscopic methods. Convolutamine F was also isolated in addition to 
kororamide A, and both were tested for activity against chloroquine-sensitive and 
resistant strains of the parasite Plasmodium falciparum which causes Malaria. 
Both compounds were marginally active against both the chloroquine-sensitive  
and resistant strains.65  
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(93) 
 
The isolation and structural elucidation of kororamide B (94), isolated from A. 
tortuosa, highlights the recent advancements in NMR and MS based dereplication 
procedures. Small scale extractions of A. tortuosa were mixed and purified by 
solid phase extraction (SPE), and HPLC. The presence of three known brominated 
alkaloids were detected by their MS and NMR features, kororamide A (93), 
convolutamine J (80) and convolutamine I (79), as well as that of a previously 
unidentified brominated alkaloid. A large scale extraction of A. tortuosa following 
the same methods as above was carried out to isolate enough of the unknown 
alkaloid for comprehensive structural elucidation. Researchers found this 
unknown metabolite to be kororamide B (94) a tryptophan-based metabolite. 
Kororamide B also contained a hexahydropyrrolo[1,2-c]imidazole-1-one moiety 
as present in wilsonamines A and B.66  
 
 
  
38 
 
 
Pterocella vesiculosa collected from the Alderman Islands, off the North Island of 
New Zealand, yielded the compounds 5-bromo-8-methoxy-1-methyl-beta-
carboline (95), and 7-bromo-1-ethyl-beta-carboline (96). Purification and 
structural elucidation was achieved by standard methods. Compound (95) showed 
activity against Bacillus subtilis as well as two fungi with Minimum Inhibitory 
Dose (MID) values in the low µg/mL range as well as moderate activity, with a 
concentration at 50% growth inhibition (IC50) value of 5089 ng/mL, against the 
P388 murine leukaemia cell line.67 Data found in a structure-activity relationship 
study of mono-substituted beta-carboline alkaloids from bryozoans suggests that 
the bromine substituent at C-5 enhances activity.68,69 
 
 
 
(95) (96) 
 
(94) 
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From the Australasian species Euthyroides episcopalis, the interesting family of 
brominated quinone methides, the euthyroideones A-C, (97-99), have been 
reported. A collection of the bryozoan from Fiordland, off the South Island of 
New Zealand afforded the euthyroideones which was then structurally elucidated 
by standard methods including single-crystal X-ray diffraction crystallography. 
The euthyroideones show little or no activity against the P388 murine leukaemia 
cell line nor antiviral or antimicrobial activity.70  
 
   
(97) (98) (99) 
 
                                                                                                           
 
The bipyrrole alkaloids, tambjamines have been isolated from the bryozoans, 
Sessibugula translucens,71 and Bugula dentata. Tambjamines A-D,72 (100-103), 
were isolated from methanol extracts of the bryozoan Sessibugula translucens and 
its predatory nudibranchs Tambje eliora and T. abdere. A carnivorous nudibranch 
Roboastra tigris, that preys on the Tambje nudibranchs was repelled by a yellow 
mucus produced by T. abdere which was found to contain a high level of the 
tambjamines. The nudibranch T. abdere sequesters secondary metabolites for 
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defense, taken from S. translucens.71 Tambjamines E (104) and F (105), together 
with tambjamines A (100) and C (102), were not found in a bryozoan, but were 
instead isolated from an ascidian Atapozoa sp.72 
 
Additional tambjamine alkaloids, tambjamines G-K (105-110) have been obtained 
from multiple studies on Tasmania, Australia collections of Bugula dentata. One 
collection of Bugula dentata  afforded tambjamines G-J (106-109) as well as the 
previously reported tambjamines C (102) and E (104). Tambjamines E (104), G 
(106) and I (108) were found to kill larvae of the brine shrimp Artemia salina.73 
Tambjamine K (110) was discovered in another study on a Tasmanian collection 
of  B. dentata, as well as tambjamines A (100) and B (101).74 Tambjamines J 
(109) was also found from the bryozoan’s predator, the nudibranch mollusk 
Tambje ceutae. Tambjamine K (110) displayed potent cytotoxicity against human 
tumour and non-tumour cell lines CaCo-2 (human epithelial colorectal 
adenocarcinoma cells) abd HeLa (human cervical cancer cells) as well as against 
the non-human cell lines C6 (rat glioma cells), H9c2 (rat cardiac myoblast cells) 
and 3T3-L1 (murine fibroblasts).74 
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(100) R1 =R2 = R3 = H 
(101) R1 =Br; R2 = R3 = H 
(102) R1 = R3 = H; R2 = CH2CH(CH3)2 
(103) R1 = H; R2 = CH2CH(CH3)2; R3 = Br 
(104) R1 = H; R2 = CH2CH3; R3 = Br 
(105) R1 = R3 = H; R2 = CH2CH2Ph 
(106) R1 = Br; R2 = CH2CH3; R3 = H 
(107) R1 = Br; R2 = CH2CH2CH3; R3 = H 
(108) R1 = Br; R2 = CH2CH(CH3)2; R3 = H 
(109) R1 = Br; R2 = CH2CH(CH3)2; R3 = H 
(110) R1 = Br; R2 = CH2CH(CH3)CH2CH3; R3 = H 
(111) R1 = Br; R2 = CH2CH2CH(CH3)2; R3 = H 
 
 
The chartellines A-C, (112-114), are unusual beta-lactam-imidazole alkaloids 
found in the bryozoan Chartella papyracea collected off the coast of Roscoff, 
France. Chartelline A was first to be isolated using common chromatographic 
methods.75 After the initial investigation of C. papyracea, two further members of 
the family, chartellines B (113) and C (114), as well as a chlorinated methoxy 
analogue of chartelline A (112), methoxy-dechlorochartelline A (115), an artefact 
of isolation, were obtained from an ethyl acetate extraction. The chartellines 
contain a beta-lactam ring condensed with a ten-membered heterocyclic ring 
which contains three degrees of unsaturation. The chartellines differ amongst 
themselves in the positioning and extent of halogenation.76  
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(112) R1 = Cl; R2 = R3 = Br 
(113) R1 = Cl; R2 = Br R3 = H 
(114) R1 = Cl; R2 = R3 = H 
(115) R1 = OCH3; R2 = R3 = Br 
 
Further brominated alkaloids, the chartellamides A (116) and B (117) were 
isolated from C. papyracea. Like the chartellines, compounds (116) and (117) are 
beta-lactam-imidazole alkaloids, however they contain a complex hexacyclic 
skeleton.77  
 
(116) R=H 
(117) R=Br 
 
Another family of brominated beta-lactam alkaloids have been reported from a 
bryozoan belonging to the same family (Flustridae) as C. papyracea. A North Sea 
collection of Securiflustra securifrons afforded the securamines A-D, (118-121). 
The general conformation of the securamines is similar to that of the previously 
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reported beta-lactam alkaloids from C. papyracea. Securamines B (119)  and C 
(120) are brominated analogues of securamines A (118)  and D (121).78 The other 
members of the family were isolated from a separate study on S. securifrons. 
Additionally, structural variants of tambjamine C  (102) were found, securamines 
E-G, (122-124) respectively.79 In the initial study of S. securifrons, the isolation of 
securines A (125) and B (126) were reported.  Researchers observed that the 
securines were present in equilibrium with securamides A and B respectively, 
when securamine A and B were dissolved in deuterated dimethyl sulphoxide-d6 
(DMSO-d6).  
 
 
(118) R = H 
(119) R = Br 
(120) R1=R2=H  
(121) R1=Br; R2=H  
(122) R1=R2=Br 
(123) R1=Br; R2=H 
 
 
(124) 
(125) R=H 
(126) R=Br 
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An extract of Indo-Pacific collections of Caulibugula intermis showed 
cytotoxicity in a National Cancer Institute (NCI) 60 cell line antitumour screen, 
prompting further investigation of the extract. Six new compounds, 
caulibugulones A-F, (127-132), were isolated from bioactivity guided 
fractionation of a cytotoxic aqueous extract.  The caulibugulones are isoquinoline, 
quinones, or iminoquinone-based metabolites but caulibugulone B (128) is the 
only brominated member of the family. The caulibugulones showed potent 
cytotoxicity, with the highest activity being reported for caulibugulone E (130), 
which had an IC50 of 0.03 µg/mL
-1 against the murine IC-2WT Cell Line. 
Bromination did not seem to have a substantial effect on the cytotoxicity of the 
caulibugulones as caulibugulone B (128) had an IC50 of 0.22 µg/mL against the 
same cell line whereas calibugulone A (127), a debrominated form of 
caulibugulone B had an IC50 of 0.34 µg/mL.
80 
 
  
(127) R1 = H; R2 = CH3 
(128) R1 = Br; R2 = CH3 
(129) R1 = Cl; R2 = CH3 
(130) R1 = H; R2 = CH2CH3OH 
(131) R = H 
(132) R = CH2CH2OH 
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2 Chapter Two  
Survey of Bryozoan Species for Brominated 
Natural Products 
 
2.1 Introduction 
As discussed in chapter one, bromination is a common feature of marine 
metabolites in general, and is especially prevalent in bryozoan metabolites. 
Sixteen bryozoan samples have been surveyed for the presence of bromine 
containing compounds, by LCMS, with the intention to discover possible novel 
compounds of significance. Small scale, crude organic extracts of bryozoans, 
collected from the United Kingdom and New Zealand, were analysed for 
characteristic bromine isotope patterns. From the sixteen samples of bryozoans 
surveyed, six species contained ions representative of the presence of at least one 
brominated compound. The data of only one compound, from the species Amathia 
verticillata (formerly Zoobotryon), could be matched with previously isolated 
metabolites, indicating that five samples surveyed most likely contain novel 
brominated metabolites.  
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2.2 Survey by Liquid Chromatography-Mass spectrometric 
Analysis 
The natural isotopic abundance of bromine, 79Br:81Br 1:1, gives brominated 
compounds very distinctive isotopic peak patterns in mass spectrometry. For 
example, bromine in monobrominated compounds contributes two peaks with 
equal intensities two mass units apart. In dibrominated compounds, bromine 
contributes three peaks with intensities of 1:2:1, every peak being two mass units 
apart. LCMS chromatograms of small scale, crude extracts of sixteen bryozoan 
species collected in 2013 and 2014 were analysed by manual peak picking to 
generate a mass spectrum for each significant peak. The resulting mass spectra 
were examined for evidence of bromination, indicated by characteristic isotope 
patterns. A complete species list with collection data as well as their LCMS traces 
with mass spectra of each significant peak is recorded in Appendix A. Bromine 
containing compounds were identified in six of the sixteen bryozoan species 
investigated (Table 2.1). 
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Table 2.1. Species surveyed containing brominated natural products  
Species 
Brominated 
compounds, M+H+ 
(m/z) (lowest 
monoisotopic peak) 
Number of 
bromine atoms 
Bugula neritina 321.9 2 
452.8 3 
Orthoscuticella, 
Costaticella (or  
another 
Catenicellidae 
species)  
261.0, 303.1 
304.0 
1 
Orthoscuticella, 
Costaticella (or  
another 
Catenicellidae 
species) 
221.9, 239.0 1 
Amathia verticillata 
(Formerly 
Zoobotryon 
verticillatum ) 
208, 222.0 
 
1 
299.9, 285.9, 344.9 2 
377.8, 422.8 3 
Amathia citrina 359.03, 436.9, 482.9, 
468.9, 498.9, 479.9 
2 
514.9 3 
592.7 4 
Amathia imbricata 
 
316.0, 252.9, 208.0 1 
436.9 2 
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The two species of Orthoscuticella or Costaticella (or another Catenicellidae 
species) analysed as well as Bugula neritina contained what appeared to be 
minute quantities of brominated compounds based on mass spectrometric analysis. 
The intensity of signals for brominated compounds found LCMS analysis of these 
species were low, approximately 1x106-5x107. In contrast, equivalently 
brominated compounds observed in A. citrina and A. verticillata had intensities of 
at least one magnitude greater, generally 1x108 to 1x109. Bromine containing 
compounds are generally easily ionisable, thus small intensities suggest very 
small concentrations of brominated compounds exist, therefore A. citrina and A. 
verticillata should have the greatest concentrations of brominated compounds of 
all species surveyed.  
 
A. citrina contained the greatest number of compounds with bromine functionality, 
as well as the only tetrabrominated compound observed. The chromatograms 
obtained from LCMS analysis including the mass spectra of the A. citrina and A. 
verticillata extracts are displayed in Figures 2.1 and 2.2 respectively.  
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(Figure 2.1 continued) 
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Figure 2.1. Chromatogram and mass spectra of Amathia citrina extract from 
LCMS analysis 
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Figure 2.2. Chromatogram and mass spectra of Amathia verticillata extract from 
LCMS analysis 
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Dereplication is an important preliminary step in natural products research to 
prevent rediscovery of known compounds. LCMS analysis of crude extracts and 
database searches of observed masses served to provide a quick dereplication step. 
The comprehensive marine natural products literature database MarinLit,81 was 
used to search for brominated compounds observed in the surveyed species, based 
on mass (nominal, ±0.6 g/mol), bromine functionality and taxonomy. Of the 
twenty six brominated compounds observed from the six bryozoan species, fifteen 
matched known compounds by mass and bromination patterns, however the 
known compounds originate from different taxa, mostly sponges and algae (see 
Table 2.2). 
 
Only two surveyed compounds observed in the survey appeared to match known 
compounds originating from comparable taxonomy (genus or species) based on 
mass and bromination patterns. The compounds with nominal masses of 422 
([M+H]+ = m/z 422.8) and 344 ([M+H]+ = m/z 344.9) from the species A. 
verticillata matched 2,3,5-tribromo-N-methylgramine (41) and 2,6-dibromo-N-
methylgramine (45) reported from collections of A. verticillata from USA44 and 
Brazil.46 The other surveyed compounds are most likely novel. B. neritina 
collected from New Zealand waters did not contain bryostatins, consistent with 
previous analysis of New Zealand samples of this species by our group and 
others.82 
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Table 2.2. Compounds from surveyed species with mass and bromination patterns 
matching known compounds and their sources   
Surveyed Species 
Compound 
mass 
(nominal ± 
0.6 g/mol) 
Source species of previously 
isolated compound 
B. neritina 320 Amathia convoluta59 
Orthoscuticella, Costaticella 
or Catenicellidae sp. 
238 Mycale fibrexilis,83 
 Didemnum candidum84 
Orthoscuticella, Costaticella 
or Catenicellidae sp. 
260 Rhodomela confervoides,85 
Alglaophenia pluma linnaeus86 
A. verticillatum 344 Plocamium cartilagineum,87 
Ochtodes crockeri,88  
Aplysia kupodai,89  
Snenosongia echina90 
330 Polyfibrospongia maynardii91 
A. citrina 
 
 
436 Ritterella rubra,92 
Laurencia tenera,93 
Psammaplysilla purpurea94 
422 Psammalplysilla purpurea,95 
Laurencia obtusa96 
468 Polysiphonia lanosa,97 Laurencia 
glandulifera,98 
Pharmacelocarpus abillardieri99 
498 Hexadella sp.100 (sponge) 
480 Laurencia irieii,101 
Suberea clavata102 
464 Aplysia depilans,103 
Sphaerococcus coronopifolis,104 
Aplysia punctata,105 
 leathesia nana106  
592 Ritterella rubra92 
A. imbricata 315  Pseudoceratina crassa,107 
Rhodomela confervoides108  
252 Pseudosuberites hyalinus,109 
paramuricea clavata110 
 
  
54 
 
Convolutamine G, a beta-phenylethylamine compound, from the bryozoan 
Amathia convoluta59 matched the mass (320 g/mol) and bromination pattern of a 
compound observed in the New Zealand collection of B. neritina. No other 
members of the convolutamines were observed. Convoultamines have thus far 
only been observed in two species of Amathia, not Bugula, thus it is unlikely that 
this compound actually is convolutamine G.  
 
From all species surveyed, A. citrina was the most promising candidate for a 
natural products study. Due to the many brominated compounds present with high 
ion intensities in LCMS, the unlikely possibility of rediscovering already known 
compounds and a large collection available (583.35g, lyophilised mass), A. citrina 
was selected as the candidate for this natural products study.   
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3 Chapter Three  
Amathamines: Brominated Indole Alkaloids 
from Amathia citrina 
 
3.1 Introduction 
Among the many brominated compounds observed from A. citrina two 
compounds were investigated in most detail. Compounds with nominal masses of 
514 and 468 g/mol were targeted for isolation to afford samples of adequate purity 
for structural analysis. The compounds with the nominal masses of 514 and 468 
g/mol, tentatively called amathamines A (133) and B (134) respectively, were 
partially characterised by MS and NMR spectroscopy A putative structure for 
other members of this family of alkaloids are proposed based on tandem MS data, 
called amathamines B (135) and C 498 (136). 
  
(133) (134) 
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(135) (136) 
 
A sample of amathamine A had been isolated previously by Chris Lockley, a 
former group member of our Natural Products Group, from a collection of A. 
citrina, without structural elucidation.111 This sample was used for 
characterisation, in conjunction with a sample of amathamine A (133) isolated 
during the course of work described in this thesis. Spectral differences were 
observed between purified samples of amathamine A despite these compounds 
having the same mass of 514 g/mol.  
 
 Heteronuclear 1H-13C connectivity NMR experiments HSQC and HMBC coupled 
with computer-generated predictive NMR spectral data for the proposed structures 
were invaluable during structural elucidation. The NMR and tandem MS data for 
amathamine A is recorded in Appendices B and C respectively. 
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3.2 Isolation and characterisation amathamine A 
3.2.1  Introduction 
Based on analysis of MS and NMR data the structure of amathamine A (133) was 
determined to be a tri-brominated indole alkaloid with N-methyl pyrrolidine and 
brominated imidazole moieties (133). LCMS guided fractionation of the crude 
extract by reversed-phase and size exclusion chromatographic steps afforded a 
semi-pure sample.  
 
(133) 
 
3.2.2 Isolation of Amathamine A 
From LCMS data on the crude extract of A. citrina the compound having the 
nominal mass of 514 g/mol was identified as tri-brominated by its characteristic 
isotopic peak pattern, a quartet, with each peak two mass units apart (Figure 3.1). 
This compound analysed for the molecular formula of C17H17N4Br3 (error: 8.1 
ppm) by HRMS analysis with an accurate monoisotopic mass of 513.9118 g/mol 
(79Br3). The isotopic peak profile matched closely that of the theoretical profile. 
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Figure.3.1. (A): HRMS spectrum of amathamine A [M+H]+. (Black) and 
Predicted Mass Spectrum of [C17H17N4Br3+H]
+ (Red). (B) [514+Na]+, presence of 
sodium adduct confirmed molecular mass. 
 
 
This compound, tentatively called amathamide A, eluted in MeOH fractions of 
crude extract processed on reversed-phase flash column chromatography. The 
MeOH fractions were combined and extensively subjected to chromatographic 
techniques, guided by LCMS analysis. An eleven step fractionation method was 
utilised, comprised of multiple reversed-phase and size exclusion 
chromatographic steps (see Appendix H). Amathamine A proved extremely 
difficult to isolate because of closely eluting contaminates, most notably a 
compound with a nominal mass of 340.9 g/mol. After isolation, sample purity was 
A 
B 
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deemed adequate for NMR spectroscopic analysis by visual observation of Base 
Peak Chromatogram (BPC) traces in LCMS (Figure 3.2). The sample was 
insoluble in deuterated chloroform (CDCl3) but readily soluble in deuterated 
methanol (CD3OD). NMR analysis was only utilised for structural elucidation, not 
purity determination because of the budget constraints imposed by the use of 
CD3OD.  
 
 
Figure 3.2. (Above) BPC trace of sample containing amathamine A isolated during 
the work described in this thesis. (Below) averaged mass spectrum. 
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A sample of a tribrominated compound with the nominal mass of 514 g/mol, 
reported to have the same molecular formulae of C17H17N4Br3, had been 
previously isolated from a smaller sample of A. citrina by Chris Lockley but was 
not characterised. Determining A. citrina was still the best candidate for analysis, 
isolation of more amathamine A, from a bigger collection of A. citrina, for the 
purpose of structural elucidation was the major goal of this thesis. The time 
constraints imposed by extensive chromatographic fractionation necessary to 
isolate amathamide A and B did not leave enough time for further purification and 
characterisation after discovering the samples were insufficiently purified for 
NMR analysis. 
 
The 1H NMR spectrum of amathamine A purified during the work described in 
this thesis vaguely resembled that of the sample previously isolated. However, 
some characteristic signals were absent. Additionally, no signal observed had 
matching chemical shift values with the 1H NMR spectrum of the previously 
isolated sample. Thus it was concluded NMR spectroscopy data generated for the 
previous sample should also be utilised for characterisation, fearing insufficient 
time for rigorous spectroscopic analysis of the sample isolated during the work 
described in this thesis. Additionally, this sample is potentially an unnatural 
structural variant of amathamine A, formed during isolation. 
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3.2.3 Characterisation of Amathamine A 
The following characterisation of amathamine A was established using the tandem 
MS and NMR data generated by Chris Lockley. The 1H NMR spectrum (Figure 
3.3.) showed three aromatic signals, a singlet at δH 7.86  and two doublets at δH 
7.55 (J=1.7) and 7.34 (J=1.7). Additionally, two N-methyl resonances, singlets at 
δH 2.51 and 3.67, four downfield aliphatic signals at δH 3.25, 3.15, a complex 
proton band at approximately 2.8 (integrating for three hydrogens) and a methine 
singlet at δH 3.92 (J=7.0, 6.9) was observed. The 13C NMR spectrum (Figure 3.2.) 
revealed the presence of eight downfield quaternary carbons at δC 146.6, 138.7, 
135.6, 132.3, 112.8, 109.2, 106.0 and 104.6, three aromatic carbons at δC 139.9, 
126.88 and 121.2, two N-methyl carbons at δC 43.2 and 34.2 and four downfield 
aliphatic carbons at δC 61.8, 49.9, 32.2 and 20.0. 
 
The aromatic and downfield aliphatic carbons had correlations in a HSQC 
experiment (Appendix B.1), assigning all protons to their directly attached 
carbons. Six downfield aliphatic protons were witnessed to correlate to three 
carbons at δC 49.9, 20.0 and 32.2, two proton correlations per carbon, δH at 
3.24/2.84, 2.80/2.74, and 3.15/2.81 respectively, indicating the presence of three 
methylene carbons. The coupling constant between the two aromatic doublets of 
1.7 Hz indicated meta-positioning.  
5
9
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Figure 3.3. 1H NMR spectrum (400MHz) of amathamine A in CD3OD 
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Figure 3.4. 13C NMR spectrum (400MHz) of amathamine A in CD3OD 
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The COSY NMR spectrum (Appendix B.2) indicated that the methine and 
methylene protons exist as a separate spin system, a –CHCH2CH2CH2- moiety. 
HMBC experiment (Appendix B.3) further proved evidence for these fragments. 
The N-methyl protons, δH 2.51, showed correlations to two carbons at δC 49.9 and 
61.2. Carbons at δC 49.1, 32.2, 20.0 and 61.2 were confirmed as three methylenes 
and a methine respectively, by a DEPT-135 experiment (Appendix B.4).  These 
data thus indicated the molecule contains a pyrrolidine ring (see figure 3.4).  
 
No coupling constants could be measured in the complex proton band around δH 
2.8 on account of overlap, however splitting of a doublet of doublets at δH 3.15 
could be measured. The larger splitting of 14.8 Hz observed is probably due to 
geminal coupling to proton δH 2.81. The smaller splitting, 5.8 Hz, is likely from 
vicinal coupling to a proton of the adjacent methylene not the methine proton. The 
coupling constants for the methine proton, a doublet of doublets are 7.0 and 6.9 
Hz. The splitting expected of proton δH 3.15 is a doublet of doublets of doublets 
of doublets, however this pattern was not witnessed. No truly representative 
examples of N-methyl pyrrolidine coupling constants were found in the literature, 
however similar coupling values were observed in a fused pyrrolidine moiety of 
the tetra-cyclic alkaloid spirotryprostatin A.112  A more in-depth analysis of these 
scalar coupling interactions require further NMR spectroscopic analysis than 
carried out for structural analysis. An HMBC experiment established an indole 
moiety as outlined in Table 3.1 and Figure 3.4. The proposed structures closely 
follow predicted δC values generated by ChemDraw® software.113 
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Table 3.1. NMR data of amathamine A in CD3OD 
Position Amathamine A 
δC δH (J, Hz) HMBC  
(from 1H) 
Predicted δC 
1-N - - - - 
2 138.7 - - 132.8 
3 109.2 - - 108.8 
3a 132.3 - - 131.8 
4 121.2 7.55, d (1.7) 7a, 6, 5, 3 120.0 
5 112.8 - - 119.2 
6 126.9 7.34, d (1.7) 7a, 7, 5, 4 126.0 
7 106.0 - - 102.2 
7a 135.6 - - 134.5 
8 61.2 3.91, dd, 
(7.0,6.9) 
- 71.4 
9-N - - - - 
10 43.2 2.51 8,11 43.3 
11 49.9 3.24, m/2.85, m 12,13 60.3 
12 20.0 2.80, m/2.74, m 11,12,8 23.0 
13 32.2 3.15, dd 
(14.8,5.8)/ 
2.81, m 
8,11,12 35.8 
 
 
 
 
 
 
Figure 3.5. Key HMBC and COSY connectivities establishing the 5,7-
dibromoindole and N-methyl pyrrolidine moieties. Single headed 
arrows indicate 2-3JCH correlations. double headed arrows indicate 
COSY correlations.  
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The protons H-4 and H-6 showed strong correlations to quaternary carbons C-5 
and C-7a. H-4 had the only correlation to C-6, while H-5 had the only correlation 
to C-3 and a very weak correlation to C-3a. The positioning of the bromine atoms 
on the benzene ring was determined to be at C-5 and C-7, thus establishing the 
presence of a 5,7-dibromoindole moiety. 
 
Tandem MS analyses yielded fragment masses detailed in Table 3.2. Two 
fragmentation pathways are witnessed for tandem MS of amathamine A. 
Table 3.2. Tandem MS analysis of amathamine A. 
Parent 
Ion 
[M+H+] 
(m/z) 
MS2 
Observed 
Fragments 
(m/z) 
Mass loss to 
form MS2 
fragment 
(mass units) 
MS3 Observed 
Fragments (m/z) 
Mass loss to 
form MS2 
fragment 
(mass units) 
515 343 172 302 41 
287  56 
262 81 
220 123 
472 43 393 79 
378 94 
351 121 
173 299 
 
Fragmentation of the parent ion, m/z 515, to ion m/z 472 required the loss of 43 
mass units. Mass change is from an even nominal mass to an odd nominal mass, 
514 to 471. Applying the nitrogen rule, this indicates the loss of an uneven 
number of nitrogen atoms, one or three. Loss of three nitrogen atoms (42 mass 
units) in a fragment of 43 mass units is impossible. So the loss of 43 mass units 
must contain a single nitrogen. The remainder of the mass lost, 29 mass units, is 
accountable by C2H5, giving the molecular formula of the loss of 43 likely to be 
  
  
67 
 
 
C2H5N. Upon establishing the presence of the 5,7-dibromoindole core by NMR 
spectroscopy, it became apparent that the loss of C2H5N represents the 
fragmentation of the N-methyl pyrrolidine moiety, as shown by the fragmentation 
pathway detailed in Figure 3.6.  
 
Figure 3.6. Proposed fragmentation of the N-methyl pyrrolidine moiety. 
 
A separate constellation of 3J 1H-13C connectivities was witnessed in the HMBC 
spectrum, with no correlations to the 5,7-dibromoindole core or to the N-methyl 
pyrrolidine moiety, and indicated the presence of a bromo-indole moiety as shown 
in figure 3.7, showing these connectivities. 
 
This separate constellation contained correlations between the aromatic proton H-
16 to two quaternary carbons C-14 and C-20 and the N-methyl group C-19. The 
 
Figure 3.7. Key HMBC correlations establishing the imidazole moiety.   
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N-methyl protons H-19 showed correlations to C-20 and C-16. This separate 
constellation was proposed to be the other structural moiety, besides the N-methyl 
pyrrolidine moiety, off the 5,7-dibromoindole core. 
 
Both 15 and 79 mass unit losses were witnessed in the MS3 analysis of m/z 
515>471. These masses are indicative of the loss of a methyl and a bromine group 
respectively and are consistent with the structural characteristics of the imidazole 
moiety proposed. The imidazole moiety must be completely lost in the MS2 
fragmentation of the parent ion, m/z 515 > 343.   
 
MS2 fragmentation of the parent ion, m/z 515, to ion m/z 343 requires the loss of 
172 mass units, an even mass unit loss. Following the nitrogen rule, this requires a 
loss of an even number of nitrogen, further suggesting the presence of the 
remaining nitrogen is amongst this separate constellation, the proposed imidazole 
moiety. A degree of unsaturation principle value of three (C4H4N2Br = 
3.5/C4H5N2Br = 3) additionally indicated a brominated imidazole ring. No COSY 
correlations were observed, as expected, additionally a SELROESY (Appendix 
B.5) experiment further confirmed the connection of this moiety.  
 
Establishment of the complete structure of amathamine A, the placement of the 
pyrrolidine and imidazole moieties upon the indole core could not be confidently 
assigned by NMR spectroscopy alone. This is due to seemingly erroneous HMBC 
connectvities of the pyrrolidine protons H-8 and H-12 to carbons C-2, C-3 and C-
20. Two substituents upon the indole moiety remain un-assigned, at the two 
  
  
69 
 
 
quaternary carbons C-2 and C-3, thus the positions of the pyrrolidine and 
imidazole moieties. As observed in Figure 3.8, the HMBC spectrum of 
amathamine A focused upon the connectivities of the pyrrolidine protons at δH 
3.91 and 3.15, there appears to be strong correlations to carbons at δC 138.66 and  
104.58.  
 
Figure 3.8. HMBC spectrum of amathamine A focused upon the connectivities of 
the pyrrolidine protons at δH 3.91 and 3.15. 
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These carbons, at δC 138.66 and 104.58, were assigned as the quaternary and 
brominated carbons C-14 and C-20 of the imidazole moiety respectively, 
indicating these are potentially very long-range correlations (n JCH n>3) or 
artefacts. The structural changes necessary to satisfy these as 2-3JCH directly 
contradicts the establishing COSY, HMBC and NOE evidence for the pyrrolidine 
and imidazole moieties. Furthermore, Figure 3.8 shows the lack of connectivities 
between the pyrrolidine protons and the carbons C-3 and C-3a of the indole ring, 
vital for confident assignment.  
 
The best evidence connecting the pyrrolidine and imidazole moieties to their 
proposed positions upon the indole core is a comparison of ChemDraw® 
software113 predicted and observed chemical shift values, particularly the effect on 
C-4 by the substituent upon C-3. The predicted chemical shift value of H-4 with 
the imidazole moiety at C-3 is 125.0, whilst the predicted shift value with the 
pyrrolidine moiety at C-3 is 120.0. Positioning of the pyrrolidine at C-3 is more 
consistent with the observed chemical shift value of C-4, δC = 121.24. 
Additionally, the predicted chemical shift values of C-3 and C-3a are closer for 
this permutation as shown by the differences in the predicted and observed 
chemical shift data in Table 3.3, these structural variations are visualised in Figure 
3.9. 
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Table 3.3. Predicted chemical shift values of two permutation of amathamine A.  
Position 
Amathamine A 
Observed 
chemical 
shift 
values 
(Obs) 
Predicted 
chemical 
shift values, 
pyrrolidine at 
C-3 
(Predpyrrolidine) 
Δ(Obs-
Predpyrrolidine) 
Predicted 
chemical 
shift values, 
imidazole at 
C-3 
(Predimidazole) 
Δ(Obs-
Predimidazole) 
2 138.66 131.9 6.76 134.4 4.26 
3 109.23 108.8 0.43 99.3 9.93 
3a 132.30 131.8 0.5 132.8 -0.5 
4 121.24 120.0 1.24 125.0 5 
5 112.81 119.2 -6.39 119.2 -6.39 
6 126.88 126.0 0.88 126 0.88 
7 106.07 102.2 3.87 102.2 3.87 
7a 135.56 134.5 1.06 133.2 2.36 
 
 
 
  
Figure 3.9. Permutations of amathamine A. 
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3.2.4 Spectral Differences between Samples of Amathamine A 
A comparison of 1H NMR spectra (figure 3.10) showed a loss of the imidazole 
hydrogen at δH 7.86 in the sample of amathamine A isolated in this study. Based 
on the interpretation of a HMBC experiment (Figure 3.11) the 5,7 di-bromo indole 
core remains. Loss of the imidazole hydrogen signal at δH 7.86 was postulated to 
occur due to the substitution of the imidazole N-methyl group and this hydrogen. 
However, this was unable to be proved due to poor resolution in the HMBC 
experiment. 
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Figure 3.10. Comparison of 1H NMR spectra of amathamine A isolated during the work described in this thesis (red), and the previously isolated 
sample of amathamine A (blue)  
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Figure 3.11. HMBC NMR spectra of amathamine A isolated during the work 
described in this thesis 
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3.3 Characterisation of Amathamine B 
3.3.1 Introduction 
Utilising the same method as employed for the structural elucidation of 
amathamine A, Amathamine B was proposed to be a di-brominated indole 
alkaloid with an N-methyl hydroxy-pyrrole moiety (134). Characteristic chemical 
shift frequencies and 1H-13C heteronuclear connectivities established the presence 
of a di-brominated indole core such as in amathamine B. Development of the core 
structure led to the understanding of an N-methyl-dihydro-hydroxy-pyrrole moiety 
by two-dimensional NMR spectroscopy experiments, supported by fragmentation 
patterns in tandem MS. The sample utilised for analysis was not pure enough for 
full structural elucidation. Further purification steps were not undertaken due to 
time constraints. NMR spectroscopic data and tandem MS data for amathamine B 
are recorded in Appendices D and E respectively. 
 
(134) 
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3.3.2 Isolation of Amathamine B 
From the crude extract LCMS trace the compound having the nominal mass of 
468 g/mol was identified as dibrominated by its characteristic isotopic peak 
pattern, a triplet, peaks two mass units apart. HRMS established the accurate 
monoisotopic mass to be 467.9882 g/mol (79Br2) and analysed for C17H18N4Br2O2 
(error: 2.5ppm) (Figure 3.12). 
 
Figure 3.12. HRMS spectrum of amathamine B [M+H]+. (Black) and Predicted 
Mass Spectrum of [C17H17N4Br2O2+H]
+ (Red). 
 
This compound, tentatively called amathamide B, eluted in H2O:MeOH (3:7) 
fractions of crude extract processed on reversed-phase flash column 
chromatography. These fractions were combined and extensively subjected to 
chromatographic techniques, guided by LCMS analysis. A five step fractionation 
method was utilised, comprised of reversed-phase and size exclusion 
chromatographic steps (Appendix G.1 and 3). Amathamine B also proved 
extremely difficult to isolate because of closely eluting contaminates. After 
isolation, sample purity was also deemed adequate for NMR spectroscopic 
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analysis by visual observation of BPC trace in LCMS (see Figure 3.13). 
Amathamine B had a longer retention time than amathamine A in reversed-phase 
chromatography, indicating amathamine B is more polar.  
 
 
Figure 3.13. (Above) BPC of a sample containing amathamide B used during 
characterisation. (Below) averaged mass spectra. (Note: rising base 
line, ~25-40 minutes was determined to be liquid phase 
contamination.) 
 
3.3.3 Characterisation of Amathamine B 
The 1H NMR spectrum (Figure 3.14) indicated the sample utilised for analysis 
contained contaminants. Additional signals not belonging to amathamine B were 
observed. Integration of proton signals in the 1H NMR spectrum and HMBC 
connectivities indicated the signals of amathamide B. two large and four minor 
proton signals were witnessed in the 1H NMR spectrum. The major and minor 
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signals showed correlations in a HSQC experiment to differing carbons. In the 1H 
NMR spectrum, coupling values throughout the aromatic region were inconsistent 
with values expected of true couplings around an aromatic ring. Additionally, the 
proton spectrum shows protons at δH 7.40 and 7.32 integrate to approximately one. 
Therefore, it was established only these two signals in the aromatic region were 
from amathamine B. 
 
The 1H-NMR spectrum also contained two downfield methine protons at δH 5.24 
and 4.76, a N-methyl signal at δH 2.97, a methyl signal at δH 2.84 and two 
downfield aliphatic multiplets at δH 3.99 and 3.78 as well as other unassigned 
signals. The 13C-NMR spectrum (Figure 3.15) contained two aromatic methines at 
δ 120.3 and 126.0, two quaternary carbons at δ 106.2 and 127.1, and other carbons 
at δ 93.5, 66.79 and 55.9, as well as other signals unassigned. The coupling of the 
aromatic protons in a HMBC experiment, most notably to C3a C7a, as well as to 
C5 and C7 was similar to that of the correlations in the analysis of amathamine A 
(figure 3.10). This led to the establishment of a 5,7-dibromoindole moiety. HMBC 
connectivities established the presence of the remaining indole carbons, the 
quaternary carbons at δ 138.5 and 119.7. The tandem MS analyses of amathamine 
B are listed in Table 3.4. Two fragmentation pathways are witnessed in the 
tandem MS experiments of 469, resulting in the loss of 41/57 then 128/112 mass 
units, respectively. 
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Table 3.4. Tandem MS of amathamine B  
Parent Ion 
(m/z) 
[M+H+] 
MS2 
Fragments 
Observed 
(m/z) 
Mass loss to 
form MS2 
fragment 
(mass units) 
MS3 
Fragments 
Observed 
(m/z) 
Mass loss to 
form MS3 
fragment 
(mass units) 
469 412 57 397  15 
300 112 
221 191 
341 128 300 41 
221 120 
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Figure 3.14. 1H NMR spectrum (400MHz) of amathamine B in CD3OD 
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Figure 3.15. 13C NMR spectrum (400MHz) of amathamine B in CD3OD
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HMBC (Appendix D.1) analysis indicated the presence of an N-methyl hydroxy-
pyrrole moiety at C-3 as shown in Figure 3.16, outlining all key HMBC and 
COSY correlations. (see Table 3.5).   
 
Table 3.5. NMR data of amathamine B in CD3OD 
Position Amathamine B 
δC δH (J, Hz) HMBC  
(from 1H) 
1-N - - - 
2 - - - 
3 106.2 - - 
3a 127.3 - - 
4 120.3 7.33, s 7a, 6, 5, 3a, 3 
5 119.6 - - 
6 126.0 7.40, s 7a, 7 
7 108.5 - - 
7a 138.3 - - 
8 66.8 4.76 - 
9 159.3 - - 
10 93.4 5.24 9,8 
11-N 49.9 - - 
12 41.62 2.97 10,13 
13 42.1 3.12, m/2.55, m - 
 
 
Figure 3.16. Key HMBC and COSY correlations establishing the 5,7 di-bromo 
indole core and the N-methyl hydroxy-pyrrole moiety at C-3. Single 
headed arrows indicate HMBC correlations, whilst double headed 
arrows indicate COSY correlations. 
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The N-methyl protons H-12 showed a strong correlation to C-10 and C-13. 
Downfield methine proton H-10 showed correlations to carbons C-13, C-9 and C-
8. The other downfield methine proton H-8 showed correlations to an indole 
carbon C-3. The establishment of the two methine and a methylene were 
reinforced by HSQC (Appendix D.2) and DEPT-135 (appendix D.3) experiments. 
These data indicated the presence of an N-methyl pyrrole, with an electron 
withdrawing substitute at the double bond. The COSY NMR spectrum (Appendix 
D.4) indicated that the methylene H-13 were vicinal to the methine H-13. The 
downfield chemical shift values of the methine C-10 were observed to be 
reminiscent of an anomeric carbon of cyclic sugars. This and the identification of 
a molecular formula containing oxygen led to the placement of a hydroxyl at the 
quaternary carbon C-9.    
Formation of the MS3 fragments m/z 300 and 221 from fragment ions m/z 412 and 
314 require the loss of 41 and 112 mass units respectively. Formation of the MS2 
fragments m/z 341 and m/z 412 from the parent ion require the loss of 57 and 128 
mass units respectively. Both MS2 fragment losses differ from the MS3 fragment 
losses by 16 mass units (57-16 = 41, 128-16 = 112). Losses of 41 and 57 are 
uneven mass losses, indicating the loss of one nitrogen, as in the similar loss of 43 
in the tandem MS of compound 514, these two fragmentations occur in MS2 and 
MS3 analyses, in two different fragmentation pathways, indicating that they 
represent fragmentation of the same component. This pattern is reflected in the 
fragmentation of mz 128 and 112 mass units, both having a difference of 16 mass 
units. The even mass lost, 128 and 112 mass units, indicates two nitrogen losses in 
both fragmentations, consistent with the proposed molecular formula. Therefore, 
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two separate moieties must fragment off the indole core to give these 
fragmentation patterns a component containing one nitrogen having a mass loss of 
41/57 mass units and another component containing two nitrogen atoms 
fragmenting to give the loss of 128/112 mass units. Upon determination of the 5,7 
dibromo-indole and N-methyl hydroxy-pyrrole moieties, the mass loss of 57 was 
speculated to be the fragmentation of the N-methyl hydroxy-pyrrole moiety.  
 
Further NMR spectroscopic analysis was unsuccessful, the final structure for 
amathamide B (134) is proposed from speculation of the presence of an imidazole 
moiety as present in amathamine B, however as a methyl hydroxy-imidazole 
moiety. This is proposed due to the presence of a suspected methyl signal, δC/H = 
2.84/24.39. To satisfy the proposed molecular formula an additional hydroxyl was 
positioned upon the imidazole moiety. These positions were chosen due to the 
absence of an imidazole proton signal, expected at δH ~7.8.   
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3.4 Tandem mass spectrometric analysis of two further 
brominated compounds from A. citrina  
 
3.4.1 Introduction 
During the isolation of amathamine A and B semi-purified samples of 
amathamine C and D were generated. Tandem mass spectrometry analysis 
indicated these compounds are likely to be brominated indole alkaloids. 
Amathamine C is proposed to be a tetra-bromoinated variant of amathamine A. 
Additionally, amathamine D is proposed be a variant of amathamine B with an 
additional hydroxyl and carbonyl functionalities. Other brominated compounds 
from A. citrina were deemed insufficiently processed from their semi-crude state 
for analysis. 
 
3.4.2 Amathamine C 
The sum difference of mass between amathamine A and C is 78 g/mol, indication 
of a simple bromine substitution. Based on the interpretation of the tandem MS 
data (Appendix F.1), compound 592 (135) a tetra-bromo variant of compound 514 
was proposed. Amathamine C has a longer retention time in reversed-phase 
chromatography, indicating amathamine C is more non-polar than amathamine A, 
consistent with the proposed structure.  
  
  
86 
  
 
 
 
 As in the tandem MS analysis of amathamine A (Table 3.6) the fragmentation of 
the N-methyl pyrrolidine moiety is observed. A loss of 43 mass units in a MS2 
analysis confirmed the presence of an N-methyl pyrrolidine moiety, suggesting 
substitution of bromine likely occurs upon the imidazole ring. A tri-bromo indole 
core was disregarded because both partially purified compounds amathamine A 
(133) and B (134) contain the same 5,7-dibromo indole core. This was further 
supported by the formation of ion m/z 340.9. A mass loss of 252 mass units is 
required, and is proposed as a loss of 172+Br. A 172 mass unit loss is witnessed in 
the complete fragmentation of the imidazole moiety in tandem MS analysis of 
amathamine A. 
 
(135) 
Table 3.6. Tandem MS analysis of amathamine C  
Parent Ion 
(m/z) 
[M+H+] 
MS2 
Fragments 
Observed 
(m/z) 
Mass loss to 
form MS2 
fragment 
(mass units) 
MS3 
Fragments 
Observed 
(m/z) 
Mass loss to 
form MS3 
fragment 
(mass units) 
593 550 43 470 80 
390 160 
332 218 
239 311 
340.9 252 
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3.4.3  Amathamine D 
Based on the interpretation of the tandem MS data (Appendix F.2), the di-
bromoinated compound, with the monoisotopic mass 498 g/mol, tentatively called 
Amathamine D (136) was proposed to be a di-brominated variant of amathamine 
A with additional hydroxyl and carbonyl moieties. 
 
A mass loss of 75 mass units witnessed in the MS2 analysis of amathamine D was 
proposed to be the fragmentation of a pyrrolidine moiety with additional hydroxyl 
and carbonyl moieties. Data generated from tandem MS analyses was insufficient 
to establish other structural characteristics of amathamine D. However, as 
amathamine D was proposed as a di-brominated member of the amathamine 
family, amathamine D has a isotope pattern consistent with di-bromination, a 
substitution of the indole bromine with an additional hydroxyl was proposed. 
Amathamine D has a shorter retention time in reversed-phase chromatography, 
 
(136) 
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indicating amathamine C is more polar than amathamine A, consistent with the 
proposed structure. 
  
Table 3.7. Tandem MS analysis of amathamine D 
Parent Ion 
(m/z) 
[M+H+] 
MS2 
Fragments 
Observed 
(m/z) 
Mass loss to 
form MS2 
fragment 
(mass units) 
MS3 
Fragments 
Observed 
(m/z) 
Mass loss to 
form MS3 
fragment 
(mass units) 
469 424 75 381 43 
365 59 
345 79 
312 112 
341 158 
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3.5 Future Work 
The partial characterisation of amathamines A-D was putatively characterised 
according to information gathered. The full characterisation of amathamine A, 
sufficient for publication, was hindered by the potential very long-range HMBC 
connectivities and no establishment of the absolute configuration. The acquisition 
of an x-ray diffraction crystallographic structure should solve these two concerns. 
Additionally, the application of preparative HPLC is potentially advantageous in 
purification of the sample of amathamine A isolated in this thesis. 
 
The characterisation of amathamine B was hindered by insufficient time invested 
in isolation and NMR spectroscopic experimentation. Additionally, acquisition of 
an x-ray diffraction crystallographic structure should provide valuable structural 
information as well as an absolute configuration determination. Further 
purification of amathamines A-D is vital for further characterisation. 
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4  Chapter Four  
Experimental 
 
4.1 Commonly used Solvents and Solutions  
The solvents and the compositions of solutions used during this research are listed 
in Tables 4.1 and 4.2 respectively. MeOH and DCM used for extraction, bench 
columns and sample preparation were distilled from drum-grade before use. 
MilliQ water was distilled on an E-Pure still (Barnstead) to an approximate 
resistance of 17.9-18MΩ.  
 
Table 4.1. Solvents used within this research. 
Solvent Source 
Drum-grade dichloromethane (DCM) Merck 
Drum-grade methanol (MeOH) Merck 
HPLC-grade acetonitrile (ACN) Honeywell International 
Methanol-d4 (CD3OD) Sigma Aldrich 
Trifluoroacetic acid (TFA) Across Organics 
 
 
Table 4.2. Compositions of solutions used within this research. 
Solution Composition 
Extraction Solvent MeOH:DCM (3:1) 
LCMS Solvent A H2O + 0.01% TFA 
LCMS Solvent B ACN + 0.01% TFA 
LCMS Solvent C ACN:H2O (3:2) 
LCMS Solvent D ACN:H2O (1:1) 
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4.2 General Experimental Methods  
Column fractions greater than 10mL were collected in conical flasks, while  
fractions of 10mL and under were collected in scintillation vials. Solvent was 
removed from fractions using a rotary evaporator (Büchi) at 35˚C. Samples were 
resuspended in MeOH, transferred to scintillation vials, then dried in a heating 
block (Lab-Line Multi-Block) at 35˚C under a stream of nitrogen gas. Sample 
masses were determined to four decimal places by weighing on a four figure 
balance (Mettler, AE-160). Care was taken to ensure vials were clean before all 
weighings and free of markings and fingerprints by cleaning every vials exterior 
with MeOH. Lyophilisation was conducted using a FreeZone6 freeze-drier 
(Labconco). 
 
4.3 Commonly used Fractionation Methods  
4.3.1 Reversed-Phase Flash Column Chromatography 
Reversed-Phase flash column chromatography was carried out on C18 stationary 
phase (C18 YMC Gel ODS-A (120 Å) I-230/70 mesh). The glass column (34 x 
370mm) was packed as a slurry in MeOH, and equilibrated to H2O using 
successive column volumes of MeOH:H2O (1:1) then H2O. Samples were 
lyophilised and pulverised into a powder, by crushing with a spatula, or made up 
in minimal amounts of DCM for loading, liquid samples were transferred to the 
head of the column with a pipette while solid samples were tipped from their vials. 
Reversed-phase flash columns were run utilising a steep stepped gradient, from 
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H2O to MeOH, DCM, and, sequentially, back to H2O.  A typical solvent system 
gradient is outlined in Table 4.3 
 
Table 4.3. Typical reversed-phase solvent system gradient. 
Sollvent solution Volume (mL) 
H2O 150 
H2O:MeOH (1:1) 150 
H2O:MeOH (3:7) 150 
H2O:MeOH (1:9) 150 
MeOH (1:1) 150 
DCM:MeOH (1:1) 150 
DCM 150 
DCM:MeOH (1:1) 150 
MeOH  150 
H2O:MeOH (1:1) 150 
H2O 150 
 
4.3.2 Size Exclusion Chromatography 
Size Exclusion Chromatography was carried out on LH-20 stationary phase 
(Sephadex LH-20, Pharmacia Fine Chemicals) on 35g and 150g sized columns 
(37 x 440 mm, 55 x 440 mm) packed in MeOH. Samples were dissolved in 
minimal amounts of MeOH for loading. Size Exclusion columns were run 
isocratically with MeOH.  
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4.4 Detection and Characterisation Techniques utilised 
4.4.1 Liquid Chromatography Tandem Mass Spectrometry 
Samples were fractionated by HPLC (UltiMate 3000; Dionex) coupled to an 
electrospray ionisation (ESI)-ion trap mass spectrometer (AmaZon X; Bruker 
Daltonics) for detection. The HPLC and mass spectrometer software, Chromelon 
(Dionex) and Trap Control respectively (Bruker Daltonics) were controlled by 
Hystar (Bruker Daltonics). Injections of 20 µL were utilised with a reversed phase 
Phenomenex, Luna 5μ C18(2) 100 Å, 150 x 4.60 mm column for separation. 
Solvent gradient utilised (Table 4.4) was a multi-step gradient between two 
solvents, LCMS solvent A and LCMS solvent B. Each run used a flow rate of 
0.2mL/min with a column temperature of 25˚C. Samples were dissolved in MeOH, 
then were filtered (0.22µm LabServ Millipore filters) prior to analysis. 
 
 
 
Tandem mass spectrometry was acquired using the liquid chromatography 
parameters above but with modified mass spectrometry methodology. The m/z of 
the protonated ions of interest were selected for, with a slit-width of 2 m/z, and the 
Table 4.4 Solvent gradient for LCMS experiments 
Time 
(min) 
 
Solvent A 
(% of total volume) 
Solvent B 
(% of total volume) 
 
0 90 10 
2 90 10 
27 0 100 
39 0 100 
45 90 10 
50 90 10 
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resulting fragments were recorded. All mass chromatograms, UV chromatograms 
and mass spectra resulting were analysed in DataAnalysis (Bruker Daltonics).  
 
4.4.2 High Resolution Mass Spectrometry  
Accurate masses and molecular formulae were established using a HRESIMS 
(MicrOTOF; Bruker Daltonics). Samples were made up in distilled MeOH to a 
concentration of approximately 2 mg/mL and introduced by direct infusion. The 
instrument was calibrated before each use, within the mass range of interest, using 
sodium formate (0.2 mg/mL) as the calibrant. 
 
4.4.3 Nuclear Magnetic Resonance Spectroscopy 
All NMR spectra were recorded on a 400 MHz spectrometer (AVIII-400; Bruker 
Daltonics). Chemical shifts were recorded at 300˚K and reported relative to the 
solvent signal (CD3OD; 
1H: δ 3.31 /13C: δ 49.15). Proton spectra were acquired 
with presaturation of the signals at δ 3.31 and δ 4.78. All heteronuclear and 
homonuclear one-dimensional and two-dimensional experiments used standard 
pulse sequences. HMBC spectroscopy utilised an optimised parameter set for 2-3J 
1H-13C correlations. 
 
4.5 Work Described in Chapter Three 
4.5.1 Isolation of target compounds  
Lyophilised A. citrina (583.4 g) was collected from Mumbles Pier, Swansea, 
Wales, by Dr Joanne Porter and Michael Winsa of Herrot-Watt University, 
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Edinburgh, and exhaustively extracted with MeOH:DCM (3:1).  The sample was 
submerged in approximately 3.25L of solvent and was masticated, via blending, 
then filtered by vacuum filtration. The residue was resuspended in three more 
successive aliquots of solvent and re-masticated until the sample was completely 
extracted, affording a total of thirteen litres of supernatant. 
 
 In MeOH fractions of crude extract from reversed-phase (C18, 75g) flash column 
chromatography the unknown compound identified to be tribrominated with a 
nominal mass of 514 g/mol eluted, tentatively called amathamide A. Guided my 
LCMS analysis, these crude MeOH fractions were combined and subjected to an 
eleven step isolation process of repeated reversed-phase and size exclusion 
columns to afford a relatively pure sample of amathamide A for analysis. Detailed 
separation trees are recorded in Appendix G.1 and 2.  
 
From MeOH:H2O (7:3) fractions of crude extract from reversed-phase (C18, 75g) 
flash columns, the unknown compound identified to be dibrominated with a 
nominal mass of 468 g/mol eluted. From multiple identical crude columns 
equivalent MeOH:H2O (7:3) fractions, containing compound 468, tentatively 
called amathamide B, were combined and processed again by reversed-phase flash 
column chromatography. Fractions with the greatest purities of amathamide B, 
determined by LCMS analysis, were then treated with size exclusion 
chromatography (LH-20, 75g), followed by chromatography on a small scale 
reversed-phase flash column (C18, 10g) to afford a relatively pure fraction of 
amathamine B for analysis. Detailed separation trees are recorded in Appendix 
G.1 and.3. 
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4.5.2 Nuclear Magnetic Resonance Spectroscopic Characterisation of 
Target Compounds 
Samples for analysis were lyophilised to mitigate the contamination of water. 
Samples were dissolved in CD3OD (0.5mL, Sigma Aldrich) and transferred into 
NMR tubes. Experiments were conducted using a Broadband Inverse Probe and 
the protocol described in Section 4.4.3. Solvent evaporation and potential 
contamination of water was effectively minimised by sealing the lid of the NMR 
tube with adhesive tape. Predicted chemical shift values were generated using 
ChemDraw® Ultra software.113 
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5 Appendices 
Appendix A.1. Collection information of surveyed bryozoan species. 
Collection card 
Number  
Species Collection site 
BCC0011 
 
Bugula flabellata Tauranga, New Zealand 
BCC0015 
 
Orthoscuticella, 
Costaticella (or another 
Catenicellidae species) 
White Island, New 
Zealand 
BCC0016 
 
Orthoscuticella, 
Costaticella (or another 
Catenicellidae species) 
White Island, New 
Zealand 
BCC0017 
 
Caberea sp. 
White Island, New 
Zealand  
BCC0018 
 
Hydrozoan / Bryozoan 
Mix 
White Island, New 
Zealand 
BCC0019 
 
Hydrozoan / Bryozoan 
Mix 
White Island, New 
Zealand 
BCC0035 
 
Orthoscuticella, 
Costaticella or 
Catenicellidae sp. 
(Same as BCC0016) 
White Island, New 
Zealand  
BCC0047 
 
Bugula neritina 
Omokoroa Mooring, 
New Zealand  
- 
 
Bugula neritina Mumbles, Wales 
- 
Amathia verticillatum 
(Formerly Zoobotryon) 
Sulphur Point Mariner, 
Tauranga 
- Amathia citrina Mumbles, Wales  
- Amathia imbricata Mumbles, Wales 
- Alcyonidium hirsutum United Kingdom 
- Bugula plumosa United Kingdom 
- Schizoporella japonica United Kingdom 
- Bugula fulva Scotland 
- Eucratea loricata United Kingdom 
   
98 
  
Appendix A.2. Chromatograms of bryozoan species surveyed by LCMS. 
 
Appendix A.2.1 Bugula neritina. 
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Appendix A.2.2 Orthoscuticella, Costaticella (or another Catenicellidae species) 
BCC0016 
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Appendix A.2.3 Orthoscuticella, Costaticella (or another Catenicellidae species) 
BCC0015 
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Appendix A.2.4 Amathia imbricata 
 
 
 
  
   
102 
  
 
Appendix B.1. HSQC NMR spectrum of amathamine A 
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Appendix B.2. COSY NMR spectrum of amathamine A 
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Appendix B.3. HMBC NMR spectrum of amathamine A 
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Appendix B.4. DEPT135 NMR spectrum of amathamine A 
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Appendix B.5. Selective ROESY NMR spectrum of amathamine A, δH 7.86 selectively irradiated 
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Appendix C. Tandem MS spectra of amathamine A 
 
 
471.86
MS2 514.9 _GA1_01_416.d: +MS2(514.90), 21.9min #735
342.90
472.85
3+
MS2 514.9 _GA1_01_416.d: +MS2(514.90), 24.1min #818
220.93
4+
301.84
3+
MS3 514.9 342.9_GA1_01_417.d: +MS3(514.90->342.90), 23.7min #608
172.93
394.94
3+
MS3 516.9 (473.9)_GA1_01_240.d: +MS3(516.90->473.90), 21.9min #556
234.05
2+
379.90
3+
MS4 516.9 (473.9) (394.9)_GA1_01_242.d: +MS4(516.90->473.90->394.90), 21.9min #451
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2
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5
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Appendix D.1. HMBC NMR spectrum of amathamine B 
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Appendix D.2. HSQC NMR spectrum of amathamine B 
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Appendix D.3. DEPT135 NMR spectrum of amathamine B 
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Appendix D.4. COSY NMR spectrum of compound 468 
 
 
 
 
   
  112 
    
 
Appendix E.1. Tandem MS spectra of compound 468 
 
 
 
 
340.89
2+
411.90
MS2 469.0_GA3_01_603.d: +MS2(469.00), 21.6min #727
220.92
2+
261.97
3+
299.83
2+
MS3 469.0 340.9_GA3_01_604.d: +MS3(469.00->340.90), 21.6min #554
220.96
3+
299.84
4+
337.83
2+
MS3 469.0 411.9_GA3_01_606.d: +MS3(469.00->411.90), 21.6min #549
0.00
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0.50
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1.00
1.25
7x10
Intens.
0.0
0.2
0.4
0.6
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0
1
2
3
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Appendix F.1. Tandem MS spectra of amathamine C 
 
 
340.88
3+ 549.77
MS2 592.8 2_GE1_01_477.d: +MS2(592.80), 23.4min #784
238.80
3+
311.84
2+
389.90
1+
469.86
2+
MS3 592.8, 549.8_GE1_01_478.d: +MS3(592.80->549.80), 23.7min #600
194.02
389.88
3+
MS4 592.8, 549.8, 469.9_GE1_01_481.d: +MS4(592.80->549.80->469.90), 23.8min #484
232.01
1+
374.84
1+
MS4 592.8, 549.8, 389.9_GE1_01_504.d: +MS4(592.80->549.80->389.90), 23.8min #489
154.04
3+
232.91
1+
MS4 592.8, 549.8, 311.8_GE1_01_506.d: +MS4(592.80->549.80->311.80), 23.7min #486
0.0
0.5
1.0
1.5
6x10
Intens.
0.0
0.5
1.0
5x10
0.0
0.5
1.0
1.5
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0
1
2
3
4
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0
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3
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Appendix F.2. Tandem MS spectra of amathamine D 
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311.86
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166.05 232.87
244.90
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3+
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335.80
1+
MS4 498.9 423.9 365.0_GA1_01_677.d: +MS4(498.90->423.90->365.00), 25.1min #516
178.90
1+ 208.05
265.08
1+
287.92
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304.94
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329.93
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Appendix G.1. Separation Trees for the processing of the crude extract 
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Appendix G.2. Separation Trees for the isolation of compound 514. 
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Appendix G.3. Separation Trees for the isolation of compound 468. 
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